SG11202106171WA - Anti-btla antibodies - Google Patents
Anti-btla antibodiesInfo
- Publication number
- SG11202106171WA SG11202106171WA SG11202106171WA SG11202106171WA SG11202106171WA SG 11202106171W A SG11202106171W A SG 11202106171WA SG 11202106171W A SG11202106171W A SG 11202106171WA SG 11202106171W A SG11202106171W A SG 11202106171WA SG 11202106171W A SG11202106171W A SG 11202106171WA
- Authority
- SG
- Singapore
- Prior art keywords
- btla antibodies
- btla
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820554.2A GB201820554D0 (en) | 2018-12-17 | 2018-12-17 | BTLA antibodies |
| PCT/GB2019/053569 WO2020128446A2 (en) | 2018-12-17 | 2019-12-17 | Btla antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106171WA true SG11202106171WA (en) | 2021-07-29 |
Family
ID=65147084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106171WA SG11202106171WA (en) | 2018-12-17 | 2019-12-17 | Anti-btla antibodies |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11421030B2 (en) |
| EP (1) | EP3898684A2 (en) |
| JP (1) | JP2022517441A (en) |
| KR (1) | KR20210131997A (en) |
| CN (1) | CN113454119A (en) |
| AU (1) | AU2019411511A1 (en) |
| CA (1) | CA3120804A1 (en) |
| GB (2) | GB201820554D0 (en) |
| MX (1) | MX2021007093A (en) |
| SG (1) | SG11202106171WA (en) |
| WO (1) | WO2020128446A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| MX2023004633A (en) * | 2020-10-23 | 2023-05-12 | Anaptysbio Inc | B and t lymphocyte attenuator (btla) modulators and method of using same. |
| WO2023143565A1 (en) * | 2022-01-29 | 2023-08-03 | Hifibio (Hk) Limited | Anti-btla antibodies and uses thereof in treating cancer |
| WO2024020407A1 (en) * | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116003607B (en) * | 2023-01-03 | 2023-10-27 | 福州迈新生物技术开发有限公司 | anti-BTLA protein monoclonal antibody and cell strain, preparation method and application thereof |
| CN116103242A (en) * | 2023-01-10 | 2023-05-12 | 潍坊医学院 | ESAT6-CAR-T for targeted treatment of tuberculosis, and preparation method and application thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH11510170A (en) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | Protein Formula |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ATE531812T1 (en) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | HUMANIZATION OF RODENT ANTIBODIES |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP3523245B1 (en) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | Transgenic chromosome-introduced rodents for the production of human antibodies |
| PL1691837T3 (en) * | 2003-12-10 | 2012-11-30 | Squibb & Sons Llc | Ip-10 antibodies and their uses |
| ES2902063T3 (en) * | 2006-09-08 | 2022-03-24 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| MX2009005189A (en) * | 2006-11-15 | 2009-06-30 | Medarex Inc | Human monoclonal antibodies to btla and methods of use. |
| EP3002296B1 (en) * | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
| KR20120090037A (en) | 2009-07-31 | 2012-08-16 | 메다렉스, 인코포레이티드 | Fully human antibodies to btla |
| GB201322725D0 (en) * | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| JP2018521959A (en) * | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Modulation of immune response using BTLA agonist antibodies |
| MX2018000073A (en) | 2015-06-30 | 2018-06-27 | Sanford Burnham Med Res Inst | Btla fusion protein agonists and uses thereof. |
| KR20180100122A (en) * | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor) |
| JOP20190261A1 (en) * | 2017-05-19 | 2019-11-05 | Lilly Co Eli | Btla agonist antibodies and uses thereof |
-
2018
- 2018-12-17 GB GBGB1820554.2A patent/GB201820554D0/en not_active Ceased
-
2019
- 2019-12-17 KR KR1020217022432A patent/KR20210131997A/en unknown
- 2019-12-17 CA CA3120804A patent/CA3120804A1/en active Pending
- 2019-12-17 JP JP2021555891A patent/JP2022517441A/en active Pending
- 2019-12-17 MX MX2021007093A patent/MX2021007093A/en unknown
- 2019-12-17 AU AU2019411511A patent/AU2019411511A1/en active Pending
- 2019-12-17 EP EP19831797.6A patent/EP3898684A2/en active Pending
- 2019-12-17 CN CN201980092337.0A patent/CN113454119A/en active Pending
- 2019-12-17 WO PCT/GB2019/053569 patent/WO2020128446A2/en unknown
- 2019-12-17 GB GB2110263.7A patent/GB2595379A/en active Pending
- 2019-12-17 SG SG11202106171WA patent/SG11202106171WA/en unknown
-
2021
- 2021-05-25 US US17/330,168 patent/US11421030B2/en active Active
- 2021-12-27 US US17/562,166 patent/US20220177589A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113454119A (en) | 2021-09-28 |
| GB201820554D0 (en) | 2019-01-30 |
| WO2020128446A2 (en) | 2020-06-25 |
| JP2022517441A (en) | 2022-03-08 |
| AU2019411511A1 (en) | 2021-06-10 |
| KR20210131997A (en) | 2021-11-03 |
| US20220177589A1 (en) | 2022-06-09 |
| US20210277123A1 (en) | 2021-09-09 |
| US11421030B2 (en) | 2022-08-23 |
| EP3898684A2 (en) | 2021-10-27 |
| GB202110263D0 (en) | 2021-09-01 |
| CA3120804A1 (en) | 2020-06-25 |
| GB2595379A (en) | 2021-11-24 |
| WO2020128446A3 (en) | 2020-07-30 |
| MX2021007093A (en) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279321A (en) | Anti-sirpα antibody | |
| SG11202106214YA (en) | Novel anti-ccr8 antibody | |
| IL280780A (en) | Anti-tigit antibodies | |
| IL279352A (en) | Il-11ra antibodies | |
| GB201709808D0 (en) | Antibodies | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL278010A (en) | Galectin-10 antibodies | |
| IL289112A (en) | Anti-tigit antibodies | |
| GB201707561D0 (en) | GARP-TGF-beta antibodies | |
| IL277030A (en) | Antibodies | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| IL291068A (en) | Anti-cd73 antibodies | |
| GB201811368D0 (en) | Antibody | |
| IL284584A (en) | Anti-tigit antibodies | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| GB201817172D0 (en) | Antibody | |
| GB201905150D0 (en) | Ant-ige antibodies | |
| GB201806084D0 (en) | Antibodies | |
| GB201917480D0 (en) | Antibodies | |
| GB201900732D0 (en) | Antibodies | |
| IL289160A (en) | Anti-angpt2 antibodies | |
| GB201711785D0 (en) | Antibodies | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201819952D0 (en) | Antibodies |